EGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug Conjugates

In this segment, Dr. Sands asks Dr. Cooper to discuss the evolving role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Cooper explains that these agents are designed to deliver cytotoxic payloads directly to tumor cells by targeting TROP2, a surface antigen expressed in many epithelial cancers, thereby enhancing antitumor activity while attempting to limit off-target effects. From a clinical perspective, she highlights that these therapies are being investigated primarily in later-line settings, particularly following progression on EGFR tyrosine kinase inhibitors and other standard treatments. The discussion also touches on emerging efficacy data, including response rates and durability, as well as safety considerations that may influence their use. Dr. Cooper emphasizes that while these agents are promising, their precise placement in the treatment sequence continues to evolve. Overall, this segment highlights the growing interest in antibody–drug conjugates as a potential component of future treatment strategies in EGFR-mutated NSCLC.